Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain ACRS message board posts where the ticker symbol ACRS has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest ACRS SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-18-002071 (34 Act)  Size: 9 KB
2018-07-10 005-89137
18946296
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-037311 Size: 6 KB
2018-06-12
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036653 Size: 5 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036652 Size: 5 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036651 Size: 5 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036650 Size: 5 KB
2018-06-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-036649 Size: 5 KB
2018-06-08
8-K  Documents Current report, item 5.07
Acc-no: 0001558370-18-005179 (34 Act)  Size: 48 KB
2018-06-08 001-37581
18888070
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000038777-18-000190 (34 Act)  Size: 209 KB
2018-06-07 005-89137
18886375
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-031804 Size: 4 KB
2018-05-21
More ACRS SEC Filings


Related news from
Tue, 10 Jul 2018
13:58:01 +0000
Aclaris' Alopecia Candidate Gets Fast Track Designation
The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.
Mon, 09 Jul 2018
11:00:00 +0000
FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Areata
The FDA’s Fast Track designation is intended to facilitate the development of new therapies for serious conditions and with the potential to address an unmet medical need. A company with an investigational medicine receiving Fast Track designation may be eligible for more frequent communications with the FDA and may receive an expedited review of the new drug application.
Fri, 06 Jul 2018
14:34:02 +0000
Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.
Tue, 03 Jul 2018
20:01:00 +0000
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that on July 2, 2018 the Compensation Committee of Aclaris’ Board of Directors granted 2 non-qualified stock option awards to purchase an aggregate of 40,500 shares of its common stock and 5 restricted stock unit awards covering an aggregate of 17,300 shares of its common stock to 5 new employees under the Aclaris 2017 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
Thu, 28 Jun 2018
20:30:00 +0000
Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced positive interim data from its Phase 2 clinical trial (AA-202 Topical) of ATI-502 for the treatment of Alopecia Totalis (AT) or Alopecia Universalis (AU), the more severe variants of Alopecia Areata (AA). ATI-502, an investigational topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502) is the most advanced topical JAK inhibitor in clinical trials for AT/AU in the United States.
Tue, 26 Jun 2018
11:00:00 +0000
Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced that the first patient has been dosed in Aclaris’ Phase 2 clinical trial of its JAK inhibitor product candidate ATI-501 oral suspension in patients with two forms of Alopecia Areata (AA) known as Alopecia Totalis (AT) and Alopecia Universalis (AU).  AA is an autoimmune dermatologic condition typically characterized by patchy non-scarring hair loss on the scalp and body. More severe forms of AA include AT, which is total scalp hair loss, and AU, which is total hair loss on the scalp and body.
Fri, 15 Jun 2018
11:00:00 +0000
Aclaris Therapeutics Expands Leadership Team, Appointing Dr. David Gordon as Chief Medical Officer
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology and immunology, announced the expansion of its executive leadership team with the appointment of David Gordon, MB ChB, as Chief Medical Officer. Dr. Gordon will report to President and Chief Executive Officer, Dr. Neal Walker, and will lead Aclaris’ clinical research and medical affairs functions.  Christopher Powala, Chief Regulatory and Development Officer, has added Elaine Morefield, Ph.D to his team as Director, Product Quality.
Tue, 12 Jun 2018
11:00:00 +0000
Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris' ESKATA™ is safe and effective in treating persons with raised seborrheic keratoses
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology, and immunology, today announced the publication of the two pivotal trials leading to the FDA approval of ESKATA (hydrogen peroxide) topical solution, 40% (w/w), for the treatment of raised seborrheic keratoses (SKs) in a prestigious peer-reviewed dermatology journal, the online Journal of the American Academy of Dermatology ahead of print. The article entitled, “Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w) in patients with seborrheic keratoses: results from two identical, randomized, double-blind, placebo-controlled, Phase 3 studies (A-101-SEBK-301/302),”1 summarized the pivotal results demonstrating the safety and efficacy of ESKATA in treating raised seborrheic keratoses after one to two treatments.
Fri, 01 Jun 2018
11:40:00 +0000
Wired News - Aimmune Therapeutics Presents Data from New Pan-European Study on Psychosocial Burden Associated with Peanut Allergy at EAACI Congress 2018
LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want access to our free research report on Aimmune Therapeutics, Inc. (NASDAQ: AIMT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AIMT as the Company's latest news hit the wire. On May 30, 2018, the Company announced that it presented data from a new study on the psychosocial burden of peanut allergy in European countries at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich. Active-Investors.com is currently working on the research report for Aclaris Therapeutics, Inc. (NASDAQ: ACRS), which also belongs to the Healthcare sector as the Company Aimmune Therapeutics.
Wed, 30 May 2018
11:00:00 +0000
Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA
WAYNE, Pa., May 30, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...
Thu, 24 May 2018
20:05:00 +0000
Landec Corporation to Nominate Two New Board Directors
Landec Corporation (LNDC), a leading innovator of diversified health and wellness solutions within the branded natural food and CDMO markets, and Wynnefield Capital, Inc. announced today that Landec is nominating two new Board members at its Annual Shareholders Meeting in October 2018. The two new nominees are Andrew Powell, with over 12 years of public boardroom experience with global life science companies, and Nelson Obus, President and Chief Investment Officer of Wynnefield Capital. This recommendation follows a series of collaborative discussions between the Company and Wynnefield Capital, which is currently Landec’s third largest shareholder with a 9.7% position and which has held an ownership position that dates back nearly fifteen years.
Sat, 19 May 2018
20:10:29 +0000
Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching
The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...
Wed, 16 May 2018
11:00:00 +0000
Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting
WAYNE, Pa., May 16, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...
Tue, 15 May 2018
20:01:59 +0000
Edited Transcript of ACRS earnings conference call or presentation 8-May-18 9:00pm GMT
Q1 2018 Aclaris Therapeutics Inc Earnings Call
Tue, 15 May 2018
11:00:00 +0000
Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting
WAYNE, Pa., May 15, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...
Fri, 11 May 2018
11:00:00 +0000
Aclaris Therapeutics to Present at the 2018 American Hair Research Summit
Paul Changelian, Ph.D., Vice President, Biology, Aclaris Therapeutics, Inc. (ACRS), will speak at the 2018 American Hair Research Summit on “Preclinical to Clinical Translation of JAK Kinase Inhibitors" on May 15. Dr. Changelian will review the history of drug discovery targeting Janus kinase (JAK) enzymes. JAK inhibitors initially were conceived as drugs to reduce organ transplant rejection but gradually were found to have utility in autoimmune diseases and oncology.
Thu, 10 May 2018
21:00:00 +0000
Aclaris Therapeutics to Attend Upcoming Investor Conferences
WAYNE, Pa., May 10, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...
Tue, 08 May 2018
21:52:23 +0000
Aclaris: 1Q Earnings Snapshot
On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 98 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Tue, 08 May 2018
20:01:00 +0000
Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
•Management to Host Conference Call at 5:00 PM ET today. WAYNE, Pa., May 08, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "At VF I have met some of the greatest givers from all walks of life and from all parts of the world. I thank each of them for sharing part of their life and knowledge with me." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards